Neurizon Therapeutics' potential drug NUZ-001 for ALS gets nod for traditional FDA approval pathway
Neurizon Therapeutics shares rose as much as 14.3% to A$0.096 after the U.S. Food and Drug Administration (FDA) affirmed the potential of a traditional approval pathway for its drug NUZ-001, given substantial evidence of effectiveness in its ongoing trial. NUZ-001 is Neurizon's treatment for amyotrophic lateral scleros